8-K Announcements
6Material company update
Apr 13, 2026·SEC
Material company update
Feb 25, 2026·SEC
Material company update
Nov 5, 2025·SEC
Revolution Medicines, Inc.(RVMD)Earnings, Financials & Key Ratios
RVMD•NASDAQ
$147.21
$29B mkt cap·Price updated May 6, 2026
AboutRevolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Show more
- Revenue$0
- EBITDA-$1.17B-72.0%
- Net Income-$1.13B-88.5%
- EPS (Diluted)-5.95-66.2%
- ROE-58.07%-98.0%
- ROIC-54.33%-61.6%
- Debt/Equity0.10+62.2%
- Interest Coverage-48.80
RVMD Key Insights
Revolution Medicines, Inc. (RVMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 96 (top 4%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 13.3% in last year
- ✗Expensive at 17.2x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RVMD Price & Volume
Revolution Medicines, Inc. (RVMD) stock price & volume — 10-year historical chart
Loading chart...
RVMD Growth Metrics
Revolution Medicines, Inc. (RVMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-88.52%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-66.2%
Return on Capital
10 Years-80.65%
5 Years-37.82%
3 Years-40.51%
Last Year-53.04%
RVMD Recent Earnings
Revolution Medicines, Inc. (RVMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 3/12 qtrs (75%)
Q1 2026Latest
Feb 25, 2026EPS
$1.86
Est $1.58
-17.7%
Revenue
—
Est $4M
Q4 2025
Nov 5, 2025EPS
$1.61
Est $1.42
-13.4%
Revenue
—
Est $2M
Q3 2025
Aug 6, 2025EPS
$1.31
Est $0.94
-39.4%
Revenue
—
Est $28M
Q2 2025
May 7, 2025EPS
$1.13
Est $1.12
-0.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $1.86vs $1.58-17.7% | —vs $4M |
| Q4 2025 | Nov 5, 2025 | $1.61vs $1.42-13.4% | —vs $2M |
| Q3 2025 | Aug 6, 2025 | $1.31vs $0.94-39.4% | —vs $28M |
| Q2 2025 | May 7, 2025 | $1.13vs $1.12-0.9% | — |
Based on last 12 quarters of dataView full earnings history →
RVMD Peer Comparison
Revolution Medicines, Inc. (RVMD) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MRSN | 145.36M | 29.08 | -2.06 | 9.88% | -211.21% | -5.05% | ||
 ARVN | 678.63M | 10.61 | -8.29 | -0.3% | -30.77% | -14.25% | 0.02 | |
 BDTX | 163.43M | 2.87 | 7.36 | 30.71% | 17.78% | 18.12% | 0.13 | |
 TNGX | 3.29B | 24.20 | -27.82 | 48.29% | -162.85% | -50.3% | 0.10 | |
 NUVL | 6.74B | 101.47 | -25.82 | -45.12% | ||||
 KYMR | 6.75B | 82.71 | -22.41 | -16.72% | -6.12% | -25.02% | 0.05 | |
 AMGN | 177.87B | 329.59 | 23.16 | 9.92% | 20.95% | 89.41% | 4.55% | 6.31 |
 MGNX | 199.45M | 3.15 | -2.67 | 0.78% | -49.91% | -120.2% | 0.66 |
Compare RVMD vs Peers
Revolution Medicines, Inc. (RVMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RVMD Income Statement
Revolution Medicines, Inc. (RVMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 20.16M | 50.04M | 42.98M | 29.39M | 35.38M | 11.58M | 0 | 0 |
| Revenue Growth % | - | - | 148.16% | -14.1% | -31.62% | 20.38% | -67.27% | -100% | - |
| Cost of Goods Sold | 26.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.56M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -26.59M▲ 0% | 20.16M▲ 175.8% | 50.04M▲ 148.2% | 42.98M▼ 14.1% | 29.39M▼ 31.6% | 35.38M▲ 20.4% | 11.58M▼ 67.3% | 0▼ 100.0% | -16.56M▲ 0% |
| Gross Margin % | - | 100% | 100% | 100% | 100% | 100% | 100% | - | - |
| Gross Profit Growth % | - | 175.85% | 148.16% | -14.1% | -31.62% | 20.38% | -67.27% | -100% | - |
| Operating Expenses | 4.54M | 60.49M | 104.16M | 153.68M | 217.4M | 293.66M | 498.76M | 689.52M | 1.17B |
| OpEx % of Revenue | - | 300% | 208.15% | 357.54% | 739.7% | 830.01% | 4307.12% | - | - |
| Selling, General & Admin | 4.54M | 9.41M | 12.41M | 21.43M | 30.45M | 40.59M | 75.62M | 97.3M | 187.13M |
| SG&A % of Revenue | - | 46.66% | 24.79% | 49.85% | 103.61% | 114.71% | 653.03% | - | - |
| Research & Development | 26.59M | 51.08M | 91.75M | 132.25M | 186.95M | 253.07M | 423.14M | 592.23M | 978.68M |
| R&D % of Revenue | - | 253.33% | 183.36% | 307.68% | 636.09% | 715.3% | 3654.09% | - | - |
| Other Operating Expenses | -26.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -31.13M▲ 0% | -40.33M▼ 29.6% | -54.12M▼ 34.2% | -110.7M▼ 104.5% | -188.01M▼ 69.8% | -258.28M▼ 37.4% | -487.19M▼ 88.6% | -689.52M▼ 41.5% | -1.18B▼ 71.5% |
| Operating Margin % | - | -199.99% | -108.15% | -257.54% | -639.7% | -730.01% | -4207.12% | - | - |
| Operating Income Growth % | - | -29.55% | -34.2% | -104.54% | -69.84% | -37.38% | -88.63% | -41.53% | -71.48% |
| EBITDA | -29.94M | -38.56M | -50.78M | -104.15M | -180.68M | -248.62M | -477.88M | -677.7M | -1.17B |
| EBITDA Margin % | - | -191.25% | -101.47% | -242.31% | -614.75% | -702.72% | -4126.74% | - | - |
| EBITDA Growth % | - | -28.8% | -31.67% | -105.11% | -73.47% | -37.61% | -92.21% | -41.82% | -72.02% |
| D&A (Non-Cash Add-back) | 1.19M | 1.76M | 3.34M | 6.54M | 7.33M | 9.66M | 9.31M | 11.82M | 16.56M |
| EBIT | -31.02M | -41.67M | -51.93M | -108.46M | -187.08M | -258.28M | -487.19M | -689.52M | -1.18B |
| Net Interest Income | 2K | 661K | 2.08M | 2.17M | 917K | 9.15M | 47.18M | 86.88M | 66.46M |
| Interest Income | 105K | 777K | 2.19M | 2.24M | 929K | 9.15M | 47.48M | 86.88M | 90.69M |
| Interest Expense | 103K | 116K | 106K | 71K | 12K | 0 | 303K | 0 | 24.23M |
| Other Income/Expense | 2K | -1.46M | 2.08M | 2.17M | 917K | 9.15M | 47.29M | 88.68M | 51.07M |
| Pretax Income | -31.13M▲ 0% | -41.79M▼ 34.3% | -52.04M▼ 24.5% | -108.53M▼ 108.6% | -187.09M▼ 72.4% | -249.13M▼ 33.2% | -439.89M▼ 76.6% | -600.85M▼ 36.6% | -1.13B▼ 88.3% |
| Pretax Margin % | - | -207.24% | -103.99% | -252.5% | -636.58% | -704.14% | -3798.71% | - | - |
| Income Tax | 105K | 0 | -4.37M | -371K | 0 | -420K | -3.52M | -753K | 0 |
| Effective Tax Rate % | -0.34% | 0% | 8.4% | 0.34% | 0% | 0.17% | 0.8% | 0.13% | 0% |
| Net Income | -31.13M▲ 0% | -41.79M▼ 34.3% | -47.66M▼ 14.1% | -108.16M▼ 126.9% | -187.09M▼ 73.0% | -248.71M▼ 32.9% | -436.37M▼ 75.5% | -600.09M▼ 37.5% | -1.13B▼ 88.5% |
| Net Margin % | - | -207.24% | -95.25% | -251.63% | -636.58% | -702.95% | -3768.28% | - | - |
| Net Income Growth % | - | -34.25% | -14.06% | -126.92% | -72.98% | -32.93% | -75.46% | -37.52% | -88.52% |
| Net Income (Continuing) | -31.13M | -41.79M | -47.66M | -108.16M | -187.09M | -248.71M | -436.37M | -600.09M | -1.13B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.85▲ 0% | -1.15▼ 35.3% | -1.31▼ 13.9% | -1.62▼ 23.7% | -2.47▼ 52.5% | -3.08▼ 24.7% | -3.86▼ 25.3% | -3.58▲ 7.3% | -5.95▼ 66.2% |
| EPS Growth % | - | -35.29% | -13.91% | -23.66% | -52.47% | -24.7% | -25.32% | 7.25% | -66.2% |
| EPS (Basic) | -0.85 | -1.15 | -1.31 | -1.62 | -2.47 | -3.08 | -3.86 | -3.58 | -5.95 |
| Diluted Shares Outstanding | 36.47M | 36.47M | 36.47M | 66.6M | 72.81M | 80.63M | 113.15M | 167.74M | 190.13M |
| Basic Shares Outstanding | 36.47M | 36.47M | 36.47M | 66.6M | 72.81M | 80.63M | 113.15M | 167.74M | 190.13M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
RVMD Balance Sheet
Revolution Medicines, Inc. (RVMD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 9.44M | 85.43M | 133.98M | 454.12M | 589.77M | 660.18M | 1.88B | 2.33B | 2.08B |
| Cash & Short-Term Investments | 9.08M | 69.59M | 122.76M | 440.74M | 577.05M | 644.94M | 1.85B | 2.29B | 2.03B |
| Cash Only | 9.08M | 69.59M | 16.66M | 104.27M | 108.5M | 161.41M | 696.15M | 543.06M | 383.75M |
| Short-Term Investments | 0 | 0 | 106.1M | 336.47M | 468.56M | 483.53M | 1.16B | 1.75B | 1.64B |
| Accounts Receivable | 0 | 7.3M | 8.74M | 6.39M | 5.93M | 4.67M | 1.25M | 0 | 0 |
| Days Sales Outstanding | - | 132.19 | 63.73 | 54.29 | 73.63 | 48.21 | 39.53 | - | - |
| Inventory | 0 | 6.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 6.6M | 0 | 0 | 0 | 10.57M | 25.07M | 38.33M | 49.36M |
| Total Non-Current Assets | 5.64M | 85.16M | 86.55M | 113.28M | 148.22M | 151.75M | 182.42M | 230.67M | 279.47M |
| Property, Plant & Equipment | 5.25M | 6.87M | 7.15M | 36.34M | 71.24M | 73.74M | 100.01M | 141.82M | 165.28M |
| Fixed Asset Turnover | - | 2.93x | 7.00x | 1.18x | 0.41x | 0.48x | 0.12x | - | - |
| Goodwill | 0 | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M |
| Intangible Assets | 0 | 63.08M | 62.01M | 60.95M | 59.88M | 58.81M | 57.74M | 56.67M | 55.8M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 383K | 593K | 2.78M | 1.39M | 2.5M | 4.59M | 10.06M | 17.57M | 43.78M |
| Total Assets | 15.08M▲ 0% | 170.59M▲ 1031.4% | 220.53M▲ 29.3% | 567.4M▲ 157.3% | 737.99M▲ 30.1% | 811.93M▲ 10.0% | 2.06B▲ 153.9% | 2.56B▲ 24.1% | 2.35B▼ 8.0% |
| Asset Turnover | - | 0.12x | 0.23x | 0.08x | 0.04x | 0.04x | 0.01x | - | - |
| Asset Growth % | - | 1031.43% | 29.28% | 157.29% | 30.06% | 10.02% | 153.93% | 24.09% | -7.97% |
| Total Current Liabilities | 7.6M | 30.55M | 43.05M | 47.18M | 60.35M | 61.98M | 143.85M | 163.91M | 290.42M |
| Accounts Payable | 3.35M | 5.24M | 11.4M | 12.61M | 14.06M | 21.31M | 61.79M | 54.43M | 64.62M |
| Days Payables Outstanding | 46.03 | - | - | - | - | - | - | - | 1.42K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.47M |
| Deferred Revenue (Current) | 0 | 16.83M | 17.12M | 12.11M | 12.36M | 4.46M | 0 | 0 | 0 |
| Other Current Liabilities | 2.55M | 6.06M | 5.73M | 7.83M | 10.16M | 13.79M | 27.51M | 31.36M | 209.34M |
| Current Ratio | 1.24x | 2.80x | 3.11x | 9.63x | 9.77x | 10.65x | 13.06x | 14.20x | 7.14x |
| Quick Ratio | 1.24x | 2.58x | 3.11x | 9.63x | 9.77x | 10.65x | 13.06x | 14.20x | 7.14x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.95M | 43.38M | 24.94M | 45.55M | 75.07M | 64.76M | 91.66M | 129.18M | 432.79M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 142.23M |
| Capital Lease Obligations | 0 | 0 | 0 | 28.99M | 60.42M | 57.43M | 80.58M | 122.97M | 0 |
| Deferred Tax Liabilities | 0 | 12.19M | 7.82M | 7.44M | 7.44M | 7.03M | 3.12M | 2.35M | 2.35M |
| Other Non-Current Liabilities | 2.95M | 2.77M | 2.4M | 632K | 634K | 301K | 7.97M | 3.86M | 288.2M |
| Total Liabilities | 10.55M | 73.93M | 67.99M | 92.72M | 135.42M | 126.74M | 235.51M | 293.1M | 723.21M |
| Total Debt | 0 | 147K | 0 | 32.66M | 66.63M | 64.2M | 87.94M | 135.84M | 158.7M |
| Net Debt | -9.08M | -69.44M | -16.66M | -71.6M | -41.86M | -97.21M | -608.2M | -407.22M | -225.04M |
| Debt / Equity | - | 0.00x | - | 0.07x | 0.11x | 0.09x | 0.05x | 0.06x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -302.22x | -347.66x | -510.57x | -1559.11x | -15667.33x | - | -1607.87x | - | -48.80x |
| Total Equity | 4.53M▲ 0% | 96.66M▲ 2033.3% | 152.53M▲ 57.8% | 474.68M▲ 211.2% | 602.57M▲ 26.9% | 685.19M▲ 13.7% | 1.83B▲ 166.5% | 2.27B▲ 24.0% | 1.63B▼ 28.0% |
| Equity Growth % | - | 2033.28% | 57.81% | 211.19% | 26.94% | 13.71% | 166.52% | 24.04% | -27.98% |
| Book Value per Share | 0.12 | 2.65 | 4.18 | 7.13 | 8.28 | 8.50 | 16.14 | 13.50 | 8.58 |
| Total Shareholders' Equity | 4.53M | 96.66M | 152.53M | 474.68M | 602.57M | 685.19M | 1.83B | 2.27B | 1.63B |
| Common Stock | 0 | 0 | 0 | 7K | 8K | 9K | 16K | 18K | 19K |
| Retained Earnings | -67.93M | -109.72M | -157.39M | -265.55M | -452.64M | -701.34M | -1.14B | -1.74B | -2.87B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 74K | 116K | -376K | -1.78M | 544K | 1.32M | 3.24M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RVMD Cash Flow Statement
Revolution Medicines, Inc. (RVMD) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -25.15M | 1.21M | -49.62M | -100.06M | -147.18M | -224.4M | -350.57M | -557.44M | -897.74M |
| Operating CF Margin % | - | 6.02% | -99.15% | -232.8% | -500.78% | -634.26% | -3027.39% | - | - |
| Operating CF Growth % | - | 104.82% | -4190.35% | -101.68% | -47.09% | -52.47% | -56.23% | -59.01% | -61.05% |
| Net Income | -31.13M | -41.79M | -47.66M | -108.16M | -187.09M | -248.71M | -436.37M | -600.09M | -1.13B |
| Depreciation & Amortization | 1.19M | 1.76M | 3.34M | 6.54M | 7.33M | 9.66M | 9.31M | 11.82M | -26.96M |
| Stock-Based Compensation | 141K | 855K | 3.16M | 8.89M | 20.72M | 31.2M | 61.77M | 79.2M | 118.39M |
| Deferred Taxes | 0 | 201K | -4.37M | -375K | 0 | -419K | -3.91M | -762K | 0 |
| Other Non-Cash Items | 549K | 2.12M | 373K | 1.34M | 3.13M | -2.64M | -22.04M | -48.77M | 142.13M |
| Working Capital Changes | 4.65M | 38.06M | -4.46M | -8.3M | 8.72M | -13.49M | 40.66M | 1.17M | 0 |
| Change in Receivables | 0 | -7.3M | -1.43M | 2.34M | 464K | 1.26M | 3.42M | 1.25M | 0 |
| Change in Inventory | 0 | 0 | 0 | -2.34M | 7.68M | 0 | 0 | 0 | 0 |
| Change in Payables | 1.97M | 109K | 5.26M | 305K | 2.24M | 7.29M | 32.47M | -6.46M | 9.54M |
| Cash from Investing | -1.57M | -1.34M | -101.97M | -234.23M | -142.12M | -24.12M | -342.6M | -554.39M | 118.06M |
| Capital Expenditures | -1.57M | -1.5M | -2.59M | -2.93M | -6.53M | -10.82M | -7.73M | -10.31M | -15.99M |
| CapEx % of Revenue | - | 7.43% | 5.17% | 6.82% | 22.21% | 30.57% | 66.74% | - | - |
| Acquisitions | 0 | 160K | 6.2M | 231.3M | 135.59M | 13.3M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -231.3M | -135.59M | -13.3M | 0 | 0 | 0 |
| Cash from Financing | 22.66M | 60.85M | 98.66M | 422.78M | 294.18M | 301.43M | 1.23B | 959.41M | 621.52M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -131K | -45K | 0 | 0 | 0 | 0 | 0 | 8.04M |
| Other Financing | 22.66M | 289K | 0 | 2.71M | 2.94M | 3.39M | 836.81M | 284K | 621.52M |
| Net Change in Cash | -4.06M▲ 0% | 60.72M▲ 1595.2% | -52.93M▼ 187.2% | 88.48M▲ 267.2% | 4.88M▼ 94.5% | 52.91M▲ 983.9% | 534.74M▲ 910.6% | -153.08M▼ 128.6% | -158.16M▼ 3.3% |
| Free Cash Flow | -26.72M▲ 0% | -286K▲ 98.9% | -52.2M▼ 18153.5% | -103M▼ 97.3% | -153.71M▼ 49.2% | -235.22M▼ 53.0% | -358.3M▼ 52.3% | -567.74M▼ 58.5% | -913.73M▼ 60.9% |
| FCF Margin % | - | -1.42% | -104.32% | -239.62% | -522.99% | -664.83% | -3094.14% | - | - |
| FCF Growth % | - | 98.93% | -18153.5% | -97.29% | -49.24% | -53.03% | -52.33% | -58.45% | -60.94% |
| FCF per Share | -0.73 | -0.01 | -1.43 | -1.55 | -2.11 | -2.92 | -3.17 | -3.38 | -4.81 |
| FCF Conversion (FCF/Net Income) | 0.81x | -0.03x | 1.04x | 0.93x | 0.79x | 0.90x | 0.80x | 0.93x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RVMD Key Ratios
Revolution Medicines, Inc. (RVMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -686.98% | -82.6% | -38.25% | -34.49% | -34.74% | -38.63% | -34.75% | -29.33% | -58.07% |
| Return on Invested Capital (ROIC) | - | -266.82% | -49.77% | -30.81% | -29.26% | -33.73% | -40.46% | -33.62% | -54.33% |
| Gross Margin | - | 100% | 100% | 100% | 100% | 100% | 100% | - | - |
| Net Margin | - | -207.24% | -95.25% | -251.63% | -636.58% | -702.95% | -3768.28% | - | - |
| Debt / Equity | - | 0.00x | - | 0.07x | 0.11x | 0.09x | 0.05x | 0.06x | 0.10x |
| Interest Coverage | -302.22x | -347.66x | -510.57x | -1559.11x | -15667.33x | - | -1607.87x | - | -48.80x |
| FCF Conversion | 0.81x | -0.03x | 1.04x | 0.93x | 0.79x | 0.90x | 0.80x | 0.93x | 0.79x |
| Revenue Growth | - | - | 148.16% | -14.1% | -31.62% | 20.38% | -67.27% | -100% | - |
RVMD SEC Filings & Documents
Revolution Medicines, Inc. (RVMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
RVMD Frequently Asked Questions
Revolution Medicines, Inc. (RVMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Revolution Medicines, Inc. (RVMD) grew revenue by 0.0% over the past year. Growth has been modest.
Revolution Medicines, Inc. (RVMD) reported a net loss of $1.13B for fiscal year 2025.
Dividend & Returns
Revolution Medicines, Inc. (RVMD) has a return on equity (ROE) of -58.1%. Negative ROE indicates the company is unprofitable.
Revolution Medicines, Inc. (RVMD) had negative free cash flow of $913.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More RVMD
Revolution Medicines, Inc. (RVMD) financial analysis — history, returns, DCA and operating performance tools
Full RVMD Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates